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Highlights
Lifestyle advice and interventions for cardiovascular risk reduction: A systematic 
review of guidelines
1. Guidelines are agreed on the importance of lifestyle advice and interventions for 
cardiovascular risk reduction.
2. Majority of guidelines for cardiovascular risk reduction through lifestyle advice and 
intervention show good rigor of development.
3. Guidelines are consistent and there is a consensus on the advice given for smoking 
cessation, physical activity levels and diet. Dietary recommendations emphasise 
limiting saturated fat and salt intake, avoiding transaturated-fat and sugar, particularly 
sugar-sweetened beverages. They encourage diets rich in fruit, vegetables, fish and 
wholegrains. 
4. Guidelines differ on recommendations for specific dietary patterns and levels of 
alcohol consumption.
5. Lifestyle advice and recommendations should be actively integrated into 
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Lifestyle factors are important in preventing cardiovascular disease (CVD) development. We 
aimed to systematically review similarities and differences between current guidelines on 
primary prevention of CVD and their recommendations on lifestyle advice or intervention, in 
order to guide primary prevention programs.
Methods:
Publications in MEDLINE, CINAHL over 7 years since May 3, 2009 were identified. G-I-N 
International Guideline Library, National Guidelines Clearinghouse, National Library for 
Health Guideline finder, Canadian Medical Association InfoBase were searched. On the 
February 8, 2017, we updated the search from Web sites of organizations responsible for 
guidelines development.
Study Selection: 2 reviewers screened the titles and abstracts to identify Guidelines from 
Western countries containing recommendations for lifestyle advice and interventions in 
primary prevention of CVD. 
Data Extraction: 2 reviewers independently assessed rigor of guideline development using 
the AGREEII instrument, and one extracted the recommendations.
Results
Of the 7 guidelines identified, 6 showed good rigor of development (range 45-86%). The 
guidelines were consistent in recommendations for smoking cessation, limiting saturated fat 
and salt intake, avoiding transaturated-fat and sugar, with particular emphasis on sugar-






























































levels and diets rich in fruit, vegetables, fish and wholegrains. Guidelines differed on 
recommendations for specific dietary patterns and alcohol consumption.
Conclusions:
Current guidelines are agreed on the importance of lifestyle in the prevention of CVD with 
consensus on most factors including physical activity, smoking cessation and diet, which 
should be actively integrated in cardiovascular risk reduction programs aiming to improve 
clinical outcomes. Recommendations covering areas such as psychological factors and sleep 
are currently limited and should be considered for future prevention guidelines.
Abstract word count: 269
Abbreviations
AGREE = Appraisal for Guidelines and Research Evaluation
ASCVD = Atherosclerotic cardiovascular disease
CKD = Chronic kidney disease































































Lifestyle factors such as smoking, high calorie diets, saturated fats, high salt intake, low 
intake of fruit and vegetables, psychological factors and being sedentary are associated with 
cardiovascular disease (CVD) development[1]. It is estimated that about 60% of the CVD 
mortality decline over the 2 decades since the 1980’s was attributable to a reduction in major 
CVD risk factors, primarily smoking. The remaining reduction was attributed to 
pharmacotherapy[2,3]. A more recent analysis confirms that improvements in a number of 
modifiable risk factors including smoking, cholesterol and blood pressure can explain much 
of the reduction in coronary heart disease mortality[4]. 
Lifestyle interventions play an important role in prevention of a number of CVD outcomes 
and its promotion has been emphasized in many prevention guidelines [5-8]. Despite this, 
most people in many Western countries do not meet the recommendations for diet and 
physical activity despite known health benefits including future CVD risk reduction[9]. 
Prevention of CVD is a rapidly evolving field and the potential for long term health care 
benefits from timely, personalized risk factor assessment and intervention has been 
recognized, highlighted by both human and economic arguments of CVD 
prevention[5,10,11]. Recommended prevention strategies now predominantly use risk 
stratification based on absolute 10-year CVD risk prediction to guide management[12].
A systematic review from the US preventive Services Task Force concluded that counselling  
for diet and physical activity in persons with risk factors for CVD resulted in consistent 
improvements across various intermediate health outcomes up to 2 years follow up[9]. The 
recent American College of Cardiology (ACC) / American Heart Association (AHA) 






























































disease (ASCVD) risk in adults emphasized that lifestyle modification remains a critical 
component of health promotion and ASCVD risk reduction, both prior to and in concert with 
the use of cholesterol lowering drug therapies[13]. Healthy diet or lifestyle modifications 
were recommended as background therapy in published randomized controlled trials (RCTs) 
of cholesterol-lowering drug therapy[14].
The aim of this systematic review was to identify similarities and differences among 
recommendations on lifestyle advice and interventions from recent guidelines addressing total 
CVD risk in the context of primary prevention. By a critical appraisal, we sought to guide 
clinicians and other health care professionals that are involved in primary prevention 
programs and counselling.
1.2 Methods
1.2.1 Data sources and guideline selection
We conducted a systematic review, using our previously published search strategy, for 
guidelines containing recommendations for lifestyle interventions for a primary prevention 
population[12] (see supplementary text for search strategy). We looked at guidelines that 
dealt with total cardiovascular risk rather than specific to a single condition such as 
hypertension or hypercholesterolemia alone.
We performed a systematic literature search to identify appropriate guidelines[12]. We 
searched for published guidelines using MEDLINE and CINAHL between May 3, 2009 and 
June 30, 2016. We supplemented this by using guidelines specific databases; 1) The National 
Guideline Clearinghouse (US), 2) National Library for Health on Guidelines Finder (UK), 3) 






























































Library (http;/www.g-i-n.net). A search of a number of websites of guidelines development 
organizations was also carried out and updated on February 8, 2017 (see supplementary Table 
A1 for list). Searches were limited to national guidelines from the United States, Canada, the 
United Kingdom, Australia and New Zealand and other international guidelines written in 
English.
1.2.2 Study Selection:
References meeting the Institute of Medicine definition of guidelines were included. 
Guidelines were excluded if they did not contain recommendations for the apparently healthy 
adult population, were entirely focused on a single condition (e.g. hypertension), were not 
produced on behalf of a professional organization or were not relevant to Western countries. 
Only guidelines produced from May 2009 with an Appraisal for Guidelines and Research 
Evaluation (AGREE) II rigor of development score over 40% were included to ensure 
appropriateness and relevance of the selected guidelines.
1.2.3 Data Extraction and Quality Assessment
Titles and abstracts were assessed by 2 independent reviewers (MK and VB). Articles were 
excluded if both reviewers agreed they were not eligible. Discrepancies between reviewers 
were resolved by consensus. Both reviewers performed the final selection for full data 
extraction.
We utilized the 23-item AGREE II instrument to determine the rigor of development for each 
of the guidelines[15]. Two reviewers (MK and CVW) independently rated the 8 items on a 7-
point Likert scale in accordance with the instructions of the AGREE II committee with 






























































by expressing the sum of the individual scores as a percentage of the maximum possible 
score. Reproducibility of the 2 reviewers scores was very good, with an interclass correlation 
coefficient of 0.80 (comparing the agreement of the total rigor of development score obtained 
by the two reviewers, see supplementary Table A2). Guidelines were ranked according to 
their scores. Editorial independence from the funding body, external funding and disclosure of 
relationships with industry were also assessed.
1.2.4 Data Synthesis and Analysis
One reviewer (MK) extracted all the relevant recommendations from the guidelines that had 
an AGREE II score of greater than 40%. General lifestyle advice was the main emphasis of 
the data extraction. A recommendation matrix was produced. The matrix was divided into (1) 
a methods section, (2) target group and (3) recommended lifestyle advice. 
1.3 Results
Our search retrieved 3560, of which 187 were potentially eligible (Figure 1). On the basis of 
the abstract we excluded 133 articles.  After we reviewed the full report 47 more were 
excluded. We included 7 guidelines on total lifestyle advice or intervention for total 
cardiovascular risk reduction. Table 1 summarizes the selected guidelines with rigor scores 
and conflicts of interest. 
Six of the 7 guidelines had a rigor score of 40% or greater. The guidelines originated from the 
USA (2 guidelines), UK (2), Australia (1) and Europe (1). Table 2 to 7 summarise the 
guideline recommendations in a matrix along with levels of evidence stated in the guidelines 
where this was available. Table 2 provides a summary of the 6 guidelines with a rigor score of 
over 40%. We then provide a summary of the specific recommendations on smoking (Table 






























































sleep (Table 7). Supplementary table A3 provides an abbreviated version of the 
recommendations included in the main tables.  
1.3.1 Areas of agreement
Most of the guidelines identified high-risk categories of people that should receive intensive 
lifestyle counselling. This commonly included presence of 
1. Diabetes - although no consensus exists as to which group of diabetics (examples 
include Type 1 diabetes or diabetes with an additional risk factor such as age>60, or 
microalbuminuria)
2. Chronic kidney disease (CKD) – the most common estimated glomerular filtration rate 
cut-off was < 60mls/min/1.73m2 with one guideline using <45 mls/min/1.73m2 
(NVDP). 
3. An elevated calculated CVD risk score – although there was no consensus on the risk 
threshold, primarily due to differences in risk scores used and the end points that the 
risk scores use in their prediction.
1.3.1.1 Smoking
There was a consensus regarding the importance of smoking cessation advice. Only the 
ACC/AHA did not have recommendations on smoking as it was not in the remit of the 
guidelines specific clinical questions. Offering additional assistance, including referral to 
counselling services and pharmacotherapy, were also recommended. Most of the guidelines 
































































All guidelines agree on the importance of physical activity in CVD risk reduction. All agree 
on a minimum of 150 minutes per week of at least moderate activity. There is also general 
consensus that if vigorous activity is undertaken then the amount required is less (NVDP only 
mentions suggestions for moderate activity). They recommend 75 minutes of vigorous 
physical activity (half of the moderate requirement). Many of the guidelines also recommend 
that the physical activity takes place in bouts of 10 minutes or more. (ESC, ACC/AHA, 
CDC/AHA and JBS3). The general recommendation is to spread the activity over the course 
of the week. The 2 UK based guidelines (NICE and JBS3) and the CDC/AHA also mention 
that twice per week the activity should be of the form that also provides muscle strengthening. 
The 2 UK based guidelines also recommend referral to programs where support or 
supervision is provided for those that may need support to change their lifestyle; this is 
particularly stated for people who are considered to be at high risk of developing CVD. The 
JBS3 also recommends community-based exercise initiatives for high-risk patients.
1.3.1.3 Weight 
There is a general consensus that people who are overweight (most commonly defined as 
BMI > 25 kg/m2) or obese (most commonly defined as BMI > 30 kg/m2) should be offered 
advice and support to work towards achieving and maintaining a healthy weight. Only the 
JBS3 has reservations on weight reduction recommendations and mentions that there is 
limited evidence that weight loss in itself directly reduces CVD risk. It mentions that the 
effects of weight loss such as blood pressure (BP) reduction may have CVD reducing impact. 
It does, however, recommend weight loss in people with obstructive sleep apnoea/hypopnea 






























































1.3.1.4 Stress and psychological factors
This is only discussed in 2 out of the 6 guidelines (ESC and NVDP). They both recommend 
the assessment for depression and psychological factors. The NVDP states that risk 
assessment using the Framingham Risk score may be underestimated in those with 
depression. Only the ESC makes recommendation on the use of stress management and 
counselling on psychological risk factors as part of a multimodal intervention in those at very 
high CVD.
1.3.1.5 Dietary factors
There was a consensus between the guidelines on the importance of dietary advice being a 
cornerstone of CVD prevention.  Lifestyle factors mentioned in guidelines specifically for 
lowering of BP other than weight control, increased physical activity include moderation of 
alcohol, sodium restriction, increased consumption of fruit and vegetables and low fat dairy 
products (ESC, ACC/AHA, CDC/AHA and JBS3). The ACC/AHA guideline also mentions 
dietary patterns such as the DASH diet, the USDA food pattern or the AHA diet.
1.3.1.5.1 Saturated fats
There was a common recommendation on the lowering of intake of saturated fats and trans-
saturated fats. Three out of the six guidelines specify a recommended percentage for intake 
with recommended levels below 7% (NICE) or 10% (ESC, JBS3). The other three guidelines 
suggest limiting intake but without specifying cut-offs.
1.3.1.5.2 Fruit and vegetables
All recommendations state that diets should be rich in fruit and vegetables. Only the ESC 






























































recommend five portions of fruits or vegetables (JBS3) or more (NICE) per day. The ESC 
recommendations refer to ‘servings’ rather than portions, with between 2-3 servings of both 
fruit and vegetables per day (equivalent to about 200g of each). The remaining guidelines 




All guidelines emphasize the recommendation for intake of fish in the diet. Four of the 
guidelines recommend at least two portions per week with at least one of them being of the 
oily variety. The remaining guidelines (ACC/AHA and NVDP) generally recommend a diet 
emphasizing the intake of fish without stating any cut-offs.
1.3.1.5.4 Meat
The recommendations regarding the consumption of meat products is less prescriptive. There 
is a general recommendation for predominantly consuming white meat, such as poultry. Two 
of the guidelines specifically emphasize poultry consumption (NVDP and ACC/AHA) and 
lean meat (NVDP). The JBS3 specifically mentions the avoidance of processed meats that 
tend to be high in trans-fatty acids.
1.3.1.5.5 Grains and nuts
There was a consensus on the recommendation for the consumption of wholegrain in the diet 
and other sources of fibre. There are general recommendations made encouraging regular 
intake of wholegrain, beans, seeds and nuts. Only the NICE guideline recommends a specific 
quantity and suggests at least 4-5 portions of unsalted nuts, seeds and legumes per week. The 































































There is a consensus regarding the importance of limiting salt intake in the diet. The most 
commonly recommended intake of salt was <6g/day (approximately 2,300mg of sodium). The 
lowest recommendation being from the CDC/AHA guideline for women of less than 1,500mg 
of sodium. This cut-off is also mentioned in the ACC/AHA guideline as offering additional 
BP lowering compared to the 2,400mg of sodium considered the upper limit.
1.3.1.5.7 Plant stenols and sterols
Although the ESC mentions that the use of plant stenols and sterols can lower LDL 
cholesterol they do not make a recommendation on its use. The NICE guideline very clearly 
recommends against plant stenols or sterols for primary or secondary prevention of CVD. The 
recommendations for the lowering of cholesterol through lifestyle factors is mentioned in 
most of the guidelines although most are not explicit as to which specific factors should be 
addressed beyond general advice. 
1.3.1.5.8 Oils 
Most of the guidelines do not make specific recommendations for the types of oils used for 
cooking. The ACC/AHA recommends the use of non-tropical vegetable oils and NICE 
recommend the use of olive oil, rapeseed oil or spreads from those oils and as potential 
replacement for non-saturated fats.
1.3.1.5.9 Sugar
There is a general consensus in the recommendations to reduce the amount of sugar in the 






























































sweetened beverages. The NICE guidelines also mention avoiding other food products that 
contain refined sugars, including fructose.
1.3.2 Areas of disagreement
1.3.2.1 Dietary patterns
The 2 dietary patterns that have most often been mentioned in the guidelines include the 
Mediterranean (ESC, NVDP, JBS3) and the DASH (ESC, ACC/AHA, CDC/AHA and JBS3) 
diets. The NICE guidance opted to avoid using the term Mediterranean diet in its 
recommendations as they felt the description was non-specific and they instead opted to 
recommend some of the components of what would be considered beneficial from a 
‘Mediterranean diet’ instead.
1.3.2.2 Alcohol intake
There is a general consensus on limiting the intake of alcohol. However, the limits that are set 
are variable compared to other recommendations. Only the ACC/AHA guideline does not 
mention any recommendation on alcohol intake as they stipulate it is outside the remit of the 
specific clinical questions addressed in the guideline. The CDC/AHA guideline for women 
only, recommends < 7 servings (1 serving is 4 oz. of wine). The ESC also recommends a 
similar amount for women and 14 units for men per week. The UK guidelines have a higher 
upper limit. The JBS3 recommends <21 units for men and < 14 units per week for women. 
The NICE guideline makes a more generalized recommendation of not regularly drinking 
more than 3-4 units per day for men (i.e. no more than 21-28 units /week) and not regularly 































































We identified 7 guidelines, of which 6 were rigorously developed, on lifestyle advice and 
interventions for total cardiovascular risk reduction in a primary prevention setting. There is a 
general consensus between the 6 guidelines about the importance of lifestyle in CVD risk 
reduction and it forms the cornerstone of almost all of the guidelines considered regardless of 
whether pharmacotherapy is indicated or already being taken.  The recommendation on the 
need for adequate physical activity levels, smoking cessation, limiting intake of saturated fat 
and particularly avoiding trans fats, having a diet that is rich in fruit and vegetables, that 
includes fish and wholegrain and limiting salt intake are very similar between the guidelines. 
There is also a consensus on the recommendations to reduce intake of sugars with specific 
mention of sugar sweetened beverages. This is particularly topical with the UK government’s 
introduction of the ‘sugar tax’ and this being preceded in other countries such as Brazil with 
the goal of tackling obesity and diabetes. NICE recommends against use of plant stenols and 
sterols and the ESC does not make a recommendation for their use citing the absence of 
studies with clinical endpoints[16]. The advice on intake of meat products is less clearly 
defined. There is a general trend to recommending poultry over red meat although this is not 
present in all guidelines. These areas may require further research for clarification.
There are differences noted in the recommendations for what is considered acceptable alcohol 
intake. Of note, none of the guidelines assigned a level of evidence grade to these 
recommendations. Cut-offs for limited alcohol intake were generally based on an 
interpretation of observational studies. Observational studies are useful when the association 
between alcohol intake in units with cardiovascular disease, is representative for the effect of 
an intervention leading to reduced alcohol intake. It is however uncertain whether reducing 






























































rates similar to what can be expected based on the observational studies. One recently 
published meta-analysis demonstrated that in people who drank at least three drinks per day, a 
reduction of alcohol consumption to near abstinence was associated with a significant 
reduction in blood pressure: -1.09 (95%CI -1.61 to -0.57), and a differential effect by gender 
was uncertain. It was estimated that more than 7000 inpatient hospitalisations and 678 
cardiovascular deaths would be prevented per year in the UK if people who drank more than 
two drinks per day reduced their alcohol consumption based on the blood pressure reductions 
that would be seen in this group[17]. These findings seem to conflict with the 
recommendations including higher upper intake limits. Similar meta-analyses on the effect of 
alcohol reduction on cardiovascular risk factors may help resolving the inconsistencies in 
recommendations. Stress and psychological factors were only mentioned in 2 guidelines with 
only one recommending its inclusion as part of a multimodal strategy, even though this was 
graded as a level of evidence 1A. There was no agreement on recommendation of specific 
dietary patterns, but the two most commonly mentioned include the Mediterranean and the 
DASH diets, which advocate specific macronutrients or whole foods rather than concentrating 
on micronutrients. The effectiveness of these diets has been demonstrated within multiple 
randomized trials, leading to a 1A classification in one guideline. It is however interesting that 
the NICE guideline avoids using the term Mediterranean diet in their recommendations based 
on quality of the evidence and potential ambiguity with the term. The Mediterranean diet is 
comprised of abundant fruit, vegetables, cereals, beans, nuts and seeds, with olive oil, a low 
consumption of red meat and low to moderate consumption of dairy products and wine. The 
PREDIMED randomized trial tested the potential for such a diet to reduce CVD events in 
patients at elevated CVD risk. The multivariable adjusted HRs were 0.70 (95% CI 0.54 to 
0.92) and 0.72 (95% CI 0.54 to 0.96) for groups assigned to a Mediterranean diet with extra- 






























































control group consisting of a low fat diet[18]. The Dietary Approaches to Stop Hypertension 
(DASH) study demonstrated that a diet rich in fruit, vegetables, and low fat dairy products 
reduced levels of total and saturated fat and lowered BP [19]. Although there is growing 
interest in the area of sleep quality and duration there was no mention regarding this area in 
any of the guidelines. Impact of areas such as psychological factors (including mindfulness) 
and sleep on cardiovascular health and prevention should be considered more widely by 
future guideline writing committees and recommendations based on current evidence. 
Adherence to lifestyle interventions remain suboptimal despite general consensus between the 
guideline. This appears to be a problem in primary prevention (including those with 
diabetes[20], hypertension[21] and obesity[22], and secondary prevention [23,24] and is not 
limited to specific countries. Causes for lack of compliance or adherence are multifactorial 
and may include lack of understanding/education of the condition, motivation and which 
healthcare provider delivers the advice[20,22]. However more research is needed to improve 
our knowledge of factors related to adherence and this may help to improve prevention 
program effectiveness in the long term[22].  Future studies need to focus on optimising 
patient adherence to prevention strategies, their cost-effectiveness and whether interventions 
work best when performed simultaneously or individually[25]. In the meantime, we should 
actively remind patients and assess adherence of lifestyle factors opportunistically during 
visits with healthcare professionals.
It should be borne in mind that individuals might have difficulties changing their lifestyle and 
behaviour, which is often based on long-standing behavioural patterns[26]. These factors may 
impede the ability to adopt a healthier lifestyle. In addition changing advice from medical 






























































example in the case of plant sterols[27]. Awareness of these factors may facilitate empathy 
and by providing simple and practical advice this may support behavioural change.
1.4.2 Relative risk
It is recognized that in younger patients there may be an underestimation of future risk if only 
a 10-year period is considered rather than over a longer period[5,6,16]. Therefore, lifetime or 
relative risk scores have been advocated in order to identify individuals who may be at high 
risk in the longer-term to encourage earlier recognition and implementation of lifestyle 
intervention, even if pharmacotherapy is not deemed necessary at that stage.
Relatively young people are at low absolute risk of a CVD event in the ensuing 10 years 
despite having many risk factors. For example, a male aged 45 years who smokes, has a 
systolic BP of 180 mmHg, and a blood cholesterol of 8 mmol/L has a risk of fatal CVD of 
only 4% over 10 years (SCORE charts), suggesting no need for drug treatment. However, the 
relative risk chart indicates that his risk is already 12-fold higher than that of a male with no 
risk factors [16].In these groups it is increasingly recognized that lifestyle intervention should 
be emphasized earlier[5,16].
1.4.3 Limitations
Some limitations could bias our findings and limit its generalizability. Only guidelines 
developed by Western national and international medical organizations dealing with total 
cardiovascular risk reduction were included. Although we did not take into account 
prevention guidelines from societies such as from Latin America or Eastern Countries, it 
should be acknowledged that even western guidelines have included evidence provided 






























































populations) in order to support their recommendations on different prevention strategies. 
Including other countries may have helped to make the findings more generalisable but may 
also have introduced more heterogeneity in areas such as diet due to cultural and geographical 
variations. We tried to control for selection bias by having a comprehensive search strategy as 
previously published and articles were appraised by 2 independent researchers. Researchers 
were not blinded to the guidelines countries of origin or the developing organizations name. 
Although we assessed the guideline development process we did not assess the clinical 
validity of the recommendations as this is not currently included in the AGREE II instrument 
and as it was beyond the scope of this review. Finally, we only emphasized lifestyle 
interventions and advice and not pharmacotherapy to avoid overlap with previous 
publications in this area. 
1.5 Conclusions
Current guidelines are agreed on the importance of lifestyle in the prevention of CVD with 
consensus on most factors including physical activity, smoking cessation and diet, which 
should be actively integrated in cardiovascular risk reduction programs aiming to improve 
clinical outcomes. Recommendations covering psychological factors and sleep are currently 
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Table 1. Characteristics of 7 Guidelines for Total Cardiovascular risk  













European Society of Cardiology Europe 86 SCIa
NICE[7], 
2014







National Health and Medical 
Research Council
Australia 85 EI,SCI b
ACC/AHA[6,
13,28], 2013
American College of Cardiology/ 
American Heart Association
United States 83 SCIa, b
CDC[29], 
2011
Centres for Disease Control and 
Prevention












































































NICE ESC (NVDP ACC/AHA CDC/ AHA BCS 
Country applied UK EUR Australia USA USA UK
 Year 2014 2016 2012 2013 2011 2014
AGREE II rigor 
Score %
86% 86% 85% 83% 65% 45%
Methods used to 
evaluate 
evidence
Systematic review Systematic review Systematic review Systematic review Systematic review Review













Review of CEA 
studies
Review of CEA 
studies
Not considered Review of CEA 
studies
Review of CEA 
studies 
Target Group Persons aged 40-74 
(NHS Health 
Check)
Men > 40-y, 
Women >50-y or 
post-menopausal
 All adults aged 
>45 y or Aboriginal 
and Torres Strait 
Islanders aged >35 
y 
Persons aged ≥ 21 Women ≥ 20 y Children and adults
High Risk 
Group
Type 1 DM, 
eGFR <60 
ml/min/1.73m2, 
aged ≥ 85 y, 
QRISK2 >10% at 
10 years
DM, > moderate 
CKD (eGFR < 
60mL/min/1.73m2) 
very high levels of 
individual risk 
factors, high 
SCORE risk (≥5%) 
and are high 
priority for 
intensive advice 
DM and aged >60 
y; DM with 
microalbuminuria 
(Males: >20 




Moderate or severe 
CKD (persistent 
 NR  NR DM, aged >40 y, CKD 
stages 3–5, Familial 
Hypercholesterolemia 
or high short-term risk 





















































ia; SBP ≥ 180 
mmHg or DBP ≥ 














































  Both target and high-
risk group: 
Counseling or group 
therapy for smoking 
cessation. 
Communicating heart 
age or lifetime risk 
















































If 10-y CHD/ 
stroke/ TIA risk 
≥10% 
If 10-y CVD 
mortality >1% or 
LDL-C 
>100mg/dL.
If 5-y CHD/stroke 
risk ≤10%.
If 5-y CHD/stroke 
risk ≥10%; more 
frequent and 
sustained lifestyle 




If 10-y CHD/ 
stroke risk ≥7.5% 
and LDL-C 70-189 
mg/dL; DM1 or 
DM2; LDL-C level 
≥190 mg/dL.
NR If Diabetes, age >40 
years, CKD stages 3–
5, Familial 
Hypercholesterolemia 
or high short-term risk 




NR NR If 5-y CHD/stroke 
risk ≥ 15%; 
according to 
clinical context. If 
5-y CHD/stroke 
risk 10%-15%; 




If 10-y CHD/ 
stroke/ TIA risk 
≥10%; on an 
ongoing basis i.e.5 
yearly as per NSF 
NR If 5-y CHD/stroke 
risk <10%; every 2 
y 
If 5-y CHD/stroke 
risk 10-15%; 
Every 6-12 months. 




If 10-y CHD/ 
stroke risk <7.5%; 
every 4-6 y.
NR NR
* Advise people who would benefit from LDL lowering; ^ Advise those who would benefit from BP lowering; €, in line with the Four commonly used methods to 












































Abbreviation: CBT, cognitive behavioral therapy, CEA , cost-effectiveness analysis, CHD , coronary heart disease, CKD , chronic kidney disease, CVD , cardiovascular 
disease, DM , diabetes mellitus, NR , not reported, NSF , National Service Framework, SCORE , Systematic Coronary Risk Evaluation, TG , triglyceride, TIA , transient 
ischemic attack, y , years
Level of evidence: A, Data derived from multiple randomized clinical trials or meta-analysis. B, Data derived from a single randomized trial or nonrandomized studies. C, 
Only consensus opinion of experts, case studies or standard of care.











































Table 3. Lifestyle recommendations for total CVD risk reduction in 6 Guidelines - Smoking
Organization NICE ESC (NVDP ACC/AHA CDC/ AHA BCS 
Smoking All smokers: advise 
to stop. 
Smokers who want 
to stop: offer 
support and advice 
and referral to 
intensive support 
services 
Smokers who are 
unable or unwilling 




and Varenicline for 
smoking cessation 
Avoid all smoking 
(IB); Avoid passive 
smoking (IB); 
Young should be 
encouraged not to 
take up smoking 
(IC); Give all 
smokers advice to 
quit and offer 
assistance (IA)
All smokers: advise 
to stop (A); Offer 
advice about 




services, and if 
assessed as nicotine 
dependent, nicotine 
replacement 




NR Women: advise not 
to smoke and avoid 
environmental 
tobacco smoke. 





conjunction with a 
behavioral program 
or formal smoking 
cessation program 
(Class I; Level of 
Evidence B). 
All smoking children 
and adults: 
professional support 
on stopping smoking 
at every available 
opportunity byself-
help material and 
referral to more 
intensive support e.g. 
stop smoking services; 
Smokers who want to 




(NRT, Varenicline or 
bupropion) or a 
combination. 
All (non-) smoking 
children and adults:
raise awareness of 
risks of active and 
passive smoking.
Abbreviation: CVD, cardiovascular disease, NR, not reported, NRT, nicotine replacement therapy, y , years
Level of evidence: A, Data derived from multiple randomized clinical trials or meta-analysis. B, Data derived from a single randomized trial or nonrandomized studies. C, 
Only consensus opinion of experts, case studies or standard of care.
















































NICE ESC (NVDP ACC/AHA CDC/ AHA BCS 
Dietary patterns  NR Mediterranean diet 
or DASH diet 




Pattern, or the 
AHA Diet (1:A) *^
DASH dietary 
pattern
Mediterranean diet or 
DASH diet
Diet If at high risk for 
CVD; advise and 
support to achieve a 
healthy diet in line 





NICE public health 
guidance 6.






 NR Advise to consume a 
diet rich in fruits and 
vegetables; choose 
whole-grain, high-
fibre foods; consume 
fish, especially oily 
fish, at least twice a 
week; limit intake of 
saturated fat, 
cholesterol, alcohol, 
sodium, and sugar; 
and avoid trans-fatty 
acids. (I:B). 
Give professional 
support to consume a 
diet associated with the 
lowest cardiovascular 
risk
Saturated fat Total fat intake ≤ 
30% of total intake, 








Should account for 






acids as little as 
possible, preferably 
no processed foods 
and <1% of total 
Diet low in 
saturated and trans-
saturated fats. Low 
fat dairy products
Reduce percentage 
of calories from 
saturated fat; 
Reduce percentage 
of calories from 
trans fat (1:A)*
Limit intake of 
saturated fats to <7% 
of total energy intake 
limit and cholesterol 
to <150mg/day (as 
found in animal 
meats, organ meats, 
eggs etc.). Avoid 
trans-fatty acids
Intake of saturated fat 
to <10% of total fat 
intake (preferably in 
lean meat and low fat 
dairy products)/ 

















































At least 5 portions 
of fruit and 
vegetables /day
200g of fruit /day 
(2-3 servings); 
200g of vegetables 
/day (2-3 servings)




of fruit and 
vegetables (1:A)*^
Diet rich in fruit and 
vegetables of ≥4.5 
cups/day servings
Consume five portions/ 
day of fruit and 
vegetables
Fish At least 2 portions 
/week, including a 
portion of oily fish
At least 2 portions/ 
week, including a 
portion of oily fish





At least 2 portions 
/week, especially 
oily fish
At least 2 portions 
/week, preferably oily 
fish 
Grains and nuts Choose wholegrain 
variety of starches. 
Eat at least 4-5 
portions of unsalted 
nuts, seeds and 
legumes / week






of legumes and nuts 
(1:A)*^
≥4/week servings per 
week of nuts 
legumes and seeds. 
(E.g. 1/2 cup or 1/2 
oz. nuts is one 
serving) Choose 
wholegrain high fiber 
foods
Consider regular 
consumption of whole 
grains and nuts 





Consume < 2,400 
mg of sodium/day; 
Further reduction to 
1,500 mg of 
sodium/day can 
lower BP more; At 
least reduce sodium 
intake by at least 
1,000 mg/day to 
lower BP (2a:B)^
< 1,500 mg of 
sodium/day 
 <6 g of salt/day
Alcohol intake Avoid binge 
drinking
Men: Limit to 3-4 
units /day
Women: Limit to 2-
3 units/day. 
Men: limit to 2 
glasses / day 
(20g/day of 
alcohol) 
Women: limit to 1 
Limit alcohol 
intake. Advised to 
follow the current 
Australian 
guidelines to 
reduce health risks 
NR ≤1/day (e.g. 4 oz. of 
wine or 12 oz. of 
beer)
Men: 
<21 units/ week 
Women: 











































glass /day (10g/day 




Oils Use olive oil, 
rapeseed oil or 
spreads based on 
those oils in food 









omega-3 fatty acids 
in the form of fish or 
in capsule form (e.g., 
EPA 1800 mg/d) 









Sugar Reduce intake of 







 NR Limit intake of 
sugars and sugar 
sweetened soft 
drinks
≤5 servings/week (≤ 
450 kcal/week) from 
sugar sweetened 
beverages (1 serving 
is 1 tablespoon of 
sugar, 1 cup of 
lemonade)
Avoid sugar sweetened 
beverages and calorie 
rich, but nutritionally 
poor, snacks such as 
sweets, cakes
Meats NR NR Varied diet rich in 





Limit saturated fat 
intake to <7% as 
found in fried foods, 




Avoid processed meats 
or commercially 
produced foods which 
tend to be high in salt 
and TFA
* Advise people who would benefit from LDL lowering; ^ Advise those who would benefit from BP lowering; €, in line with the Four commonly used methods 
to increase physical activity (NICE public health guidance 2).











































Level of evidence: A, Data derived from multiple randomized clinical trials or meta-analysis. B, Data derived from a single randomized trial or nonrandomized studies. C, 
Only consensus opinion of experts, case studies or standard of care.
















































NICE ESC (NVDP ACC/AHA CDC/ AHA BCS 
Weight Offer overweight 
and obese people 
appropriate advice 
and support to work 
towards achieving 
and maintaining a 
healthy weight (in 
line with the 
Obesity (NICE 
guideline 43)
Weight reduction in 
overweight and 
obese people is 
associated with 
favorable effects on 
BP and 
dyslipidemia, 
which may lead to 
less CVD (I:A)
Weight loss should 
be recommended 
for those who are 
overweight or 
obese (B). Limit 
energy intake to 
maintain a healthy 
weight. Ideal 
weight should be 
BMI <25 kg/m2 
and waist 
circumference <94 
cm in men (<90 cm 
in Asian men) or 




maintain a healthy 





maintain or lose 
weight through an 
appropriate balance 
of physical activity, 




maintain or achieve 
an appropriate body 
weight (e.g., BMI 
??25 kg/m2 in U.S. 
women), waist size 
(e.g., >35 in), or 
other target metric of 
obesity. (Class I:B). 
NR
* Advise people who would benefit from LDL lowering; ^ Advise those who would benefit from BP lowering; €, in line with the Four commonly used methods to 
increase physical activity (NICE public health guidance 2); *, in line with the national guidance for the general population (see physical activity guidelines for adults at 
NHS choices);
Abbreviation: BMI, body mass index, BP, blood pressure, CVD, cardiovascular disease, NR, not reported, y , years
Level of evidence: A, Data derived from multiple randomized clinical trials or meta-analysis. B, Data derived from a single randomized trial or nonrandomized studies. C, 
Only consensus opinion of experts, case studies or standard of care.
















































NICE ESC (NVDP ACC/AHA CDC/ AHA BCS 
Physical activity At least 150 
minutes of 
moderate intensity 
aerobic activity or 
75 minutes of 
vigorous intensity 
aerobic activity/ 
week. Or a mix of 
moderate and 
vigorous intensity 
physical activity. * 
Or exercise at their 
maximum safe 




Agree goals and 
provide written 
information about 
benefits and local 
opportunities to be 
active
Do 2.5 - 5 hours a 
week of physical 
activity or aerobic 
exercise training of 
at least moderate 
intensity or 1-2.5 a 
week of vigorous 
intensity exercise. 
Sedentary subjects 
should be strongly 
encouraged to start 
light intensity 
exercise programs 
(IA). / Perform in 
multiple bouts of 
>10 mins and 
evenly spread 
thought-out the 
week (i.e. 4-5 days 
/ week) (IIa:A)
All adults to 
participate in at 
least 30 minutes of 
moderate intensity 
physical activity on 
most days of the 
week, preferably 
every day (>2.5 
hours/week)(B)
Engage in 2 h and 
30 min/ week of 
moderate-intensity 
physical activity, or 
1 h and 15 min (75 
min)/ week of 
vigorous-intensity 
aerobic physical 







activity should be 
performed in 
episodes of at least 
10 min, preferably 
spread throughout 
the week; 3-4 
sessions / week of 
aerobic physical 
activity, lasting on 




for those needing to 
reduce LDL-C and 
Women should be 
advised to 
accumulate at least 
150 min/week of 
moderate exercise, 
75 min/week of 







activity should be 
performed in 
episodes of at least 
10 min, preferably 
spread throughout 
the week (Class I:B). 
Women should also 
be advised that 
additional 
cardiovascular 




activity to 5 h 
(300 min)/week, 2 
1/2 h/week of 
An increase in overall 
levels of sustained 
physical activity and 
avoidance of 
prolonged sedentary 
behavior are important 
for reduction of CVD 
risk. / Emphasize 
walking, cycling, and 
other aerobic physical 
daily activities, at 
moderate intensity, as 
part of an active 
lifestyle, for at least 
150 min/ week in 
bouts of ≥10 min, or
75 min/ week of 
vigorous physical 
activity, or a 
combination of the 
two. / Muscle 
strengthening activities 
performed on at least 












































cholesterol or BP 
(2aA)*^
vigorous-intensity 
physical activity, or 
an equivalent 






activities on 2 or 
more days of the 
week that work all 
major muscles 
groups.*
 NR NR NR Women should be 
advised to engage in 
muscle-strengthening 
activities that involve 
all major muscle 
groups performed on 
>2 d/week (Class I; 
B). / Women who 
need to lose weight 
or sustain weight loss 
should be advised to 
accumulate a 
minimum of 60 to 90 
min of at least 
moderate-intensity 
physical 
activity (e.g., brisk 
walking) on most, 
and preferably all, 
days of the week 
(Class I:B). 
Incorporating a warm 
up and cool down 
period, should be 
performed at moderate 
to high intensity, 2-3 
times per week for 30–
40 min each time. / 
The mode of exercise 
should be aerobic and, 
where  possible, 
continuous allowing 
for a steady 
progression in effort 
for example, walking 
programs, cycling, 
jogging, swimming. / 
The time spent 
exercise training 
contributes to meeting 















































Refer to programs 
such as exercise 
referral schemes for 
people who may 
need support to 
change their 
lifestyle
NR  NR NR NR If at higher risk of 
CVD: offer a more 
structured approach in 
managing patients 
All children and 
adults:  Assess and set 





Increase in exercise 
with community-based 
exercise initiatives are 
recommended for 
patients at risk of CVD
* Advise people who would benefit from LDL lowering; ^ Advise those who would benefit from BP lowering; €, in line with the Four commonly used methods to increase 
physical activity (NICE public health guidance 2).
Abbreviation: CVD, cardiovascular disease, NR, not reported, y , years
Level of evidence: A, Data derived from multiple randomized clinical trials or meta-analysis. B, Data derived from a single randomized trial or nonrandomized studies. C, 
Only consensus opinion of experts, case studies or standard of care.




















































 NR If at high risk for 


















factors. Risk may 
be FRS may 
underestimate risk 
in adults with 
depression. 
 NR  NR NR
Sleep quality or 
length
NR NR NR NR NR NR
Abbreviation: CHD , coronary heart disease, CVD , cardiovascular disease, FRS, Framingham Risk Score, NR , not reported, 
Level of evidence: A, Data derived from multiple randomized clinical trials or meta-analysis. B, Data derived from a single randomized trial or nonrandomized studies. C, 
Only consensus opinion of experts, case studies or standard of care.







































































































 Author Agreement Form – International Journal of Cardiology 
Manuscript Title: 
Lifestyle advice and interventions for cardiovascular risk reduction: A systematic review of 
guidelines
List of all Authors: 
Mohammed Y. Khanji, PhD, Claudia N. van Waardhuizen, MSc, Vinícius V. S. Bicalho, MD, Bart S. 
Ferket, PhD, Steffen E. Petersen DPhil*, M. G. Myriam Hunink, PhD* 
* Joint senior authors
Corresponding Author: 
Professor M.G. Myriam Hunink
This statement is to certify that all authors have seen and approved the manuscript
being submitted, have contributed significantly to the work, attest to the validity and legitimacy 
of the data and its interpretation, and agree to its submission to the International Journal of 
Cardiology. 
We attest that the article is the Authors' original work, has not received prior publication and is 
not under consideration for publication elsewhere.  We adhere to the statement of ethical 
publishing as appears in the International of Cardiology (citable as: Shewan LG, Rosano GMC, 
Henein MY, Coats AJS. A statement on ethical standards in publishing scientific articles in the 
International Journal of Cardiology family of journals.  Int. J. Cardiol.  170 (2014) 253-254 
DOI:10.1016/j.ijcard.2013.11). 
On behalf of all Co-Authors, the corresponding Author shall bear full responsibility for the 
submission.  Any changes to the list of authors, including changes in order, additions or removals 
will require the submission of a new author agreement form approved and signed by all the 
original and added submitting authors.   
All authors are requested to disclose any actual or potential conflict of interest including any 
financial, personal or other relationships with other people or organizations within three years of 
beginning the submitted work that could inappropriately influence, or be perceived to influence, 
their work.  If there are no conflicts of interest, the COI should read: “The authors report no 
relationships that could be construed as a conflict of interest”.
1
Supplementary Material for Online Only publication 
Table A1: Website searches of guideline development organizations, including websites 










Cardiac Society of Australia 
and New Zealand (CSANZ)
Australia http://www.csanz.edu.au
National Health and Medical 
Research Council (NHMRC)
Australia http://www.nhmrc.gov.au/index.htm







Canadian Task Force on 
Preventive Health Care 
(CTFPHC)
Canada http://canadiantaskforce.ca










International Society of 
Hypertension
International http://www.ish-world.com
World Heart Federation International http://www.world-heart-federation.org
World Health Organisation 
(WHO)
International http://www.who.int/en
World Hypertension League International http://www.worldhypertensionleague.org/Pages
/Home.aspx










Department of Health (DOH) United 
Kingdom
http://www.dh.gov.uk/en/index.htm
National Institute for Health 





American Academy of 
Family Physicians (AAFP)
United States http://www.aafp.org/online/en/home.html




American College of 
Cardiology
United States http://www.acc.org
American College of 
Physicians
United States http://www.acponline.org






American Geriatrics Society 
(AGS)
United States http://www.americangeriatrics.org






American Stroke Association United States http://www.strokeassociation.org
Centers for Disease Control 
and Prevention (CDC)/ AHA
United States http://www.cdc.gov
National Heart Lung and 
Blood Institute
United States http://www.nhlbi.nih.gov/guidelines/index.htm
New Zealand Guidelines 
Group
New Zealand http://www.nzgg.org.nz














Supplementary Table A2- AGREE II instrument: Rigor of development domain results
Guideline ESC NICE ACC/AHA NHMRC/ NVDPA CDC/AHA BCS/JBS3
Reviewer A B A B A B A B A B A B
Method to search for 
evidence
6 7 7 5 7 6 7 6 6 6 3 4
Criteria to select evidence 5 7 7 5 6 6 7 6 5 6 2 4
strengths and limitations 
of evidence
6 7 7 5 6 4 6 5 5 6 3 3
Methods for formulating 
recommendations
7 7 7 5 7 6 7 5 6 4 3 4
health benefits, side 
effects, and risks




7 6 7 5 6 5 6 5 4 5 4 4
Procedures for external 
expert review
5 5 7 6 7 6 6 6 5 7 6 6
Updating process 6 5 7 6 6 6 6 7 1 2 2 1
Domain score, % 86% 86% 83% 85% 65% 45%
4



























Country applied UK EUR Australia USA USA UK
 Year 2014 2016 2012 2013 2011 2014
AGREE II rigor 
Score %
86% 86% 85% 83% 65% 45%
Methods used to 
evaluate 
evidence
Systematic review Systematic review Systematic review Systematic review Systematic review Review




Formal consensus Formal consensus Formal consensus Formal consensus Formal consensus 
and voting
NR
Target Group Persons aged 40-74 
(NHS Health 
Check)
Men > 40-y, 
Women >50-y or 
post-menopausal
 All adults aged 
>45 y or Aboriginal 
and Torres Strait 
Islanders aged >35 
y 




If 10-y CHD/ 
stroke/ TIA risk 
≥10% 
If 10-y CVD 
mortality >1% or 
LDL-C 
>100mg/dL.
If 5-y CHD/stroke 
risk ≤10%.
If 5-y CHD/stroke 




If 10-y CHD/ 
stroke risk ≥7.5% 
and LDL-C 70-189 
mg/dL; DM1 or 
DM2; LDL-C level 
≥190 mg/dL.
NR If Diabetes, age >40 
years, CKD stages 3–
5, Familial 
Hypercholesterolaemia 
or high short term risk 
as per NICE 2014 (i.e. 
QRISK2 ≥10%)
Smoking All smokers: advise 
to stop with 
support. 
 




encouraged not to 
All smokers: advice 
to stop with 
support. 





All smoking children 
and adults: 
professional support 
on stopping smoking 
5
take up smoking; 
Give all smokers 
advice to quit and 
offer support 
at every available 
opportunity 
Dietary patterns  NR Mediterranean diet 
or DASH diet 








Mediterranean diet or 
DASH diet
Saturated fat ≤7%, Replace 




<10% of total 
energy intake. 
Trans-unsaturated 




Diet low in 
saturated and trans-
saturated fats. Low 
fat dairy products
Reduce percentage 
of calories from 
saturated fat; 
Reduce percentage 
of calories from 
trans fats*
<7% of total energy 
intake limit and 
cholesterol to 
<150mg/day (as 
found in animal 
meats, organ meats, 
eggs etc.). Avoid 
trans-fatty acids
<10% (preferably in 
lean meat and low fat 
dairy products)/ 





At least 5 portions 
of fruit and 
vegetables /day
200g of fruit /day 
(2-3 servings); 
200g of vegetables 
/day (2-3 servings)




of fruit and 
vegetables (1A)*^
Diet rich in fruit and 
vegetables of ≥4.5 
cups/day servings
Consume five 
portions/  day of fruit 
and vegetables
Fish At least 2 portions 
/week, including a 
portion of oily fish
At least 2 portions/ 
week, including a 
portion of oily fish





At least 2 portions 
/week, especially 
oily fish
At least 2 portions 
/week, preferably oily 
fish 
Grains and nuts Choose wholegrain 
variety of starches. 
Eat at least 4-5 
portions of unsalted 
nuts, seeds and 
legumes / week






of legumes and nuts 
(1A)*^
≥4/week servings per 
week of nuts 




consumption of whole 
grains and nuts 





Consume < 2,400 
mg of sodium/day^
< 1,500 mg of 
sodium/day 
 <6 g of salt/day
6
Alcohol intake Avoid binge 
drinking
Men: Limit to 3-4 
units /day
Women: Limit to 2-
3 units/day
Men: limit to 2 
glasses / day 
(20g/day of 
alcohol) 








NR ≤1 unit/day (e.g. 4 
oz. of wine or 12 oz. 
of beer)
Men: 
<21 units/ week 
Women: 
<14 units/ week 
Sugar Reduce intake of 







 NR Limit intake of 
sugars and sugar 
sweetened soft 
drinks
≤5 servings/week (≤ 
450 kcal/week) from 
sugar sweetened 
beverages (1 serving 




and calorie rich, but 
nutritionally poor, 
snacks such as sweets, 
cakes
Meats NR NR Varied diet rich in 





Limit saturated fat 
intake to <7% as 
found fat on meat or 
chicken skin
Avoid processed meats 
or commercially 
produced foods which 
tend to be high in salt 
and trans fat
Weight Offer overweight 
and obese people 
appropriate advice 
and support 
Weight reduction in 
overweight and 
obese people is 
associated with 
favourable effects 






obese. Ideal weight 
should be BMI <25 
kg/m2 and waist 
circumference <94 
cm in men (<90 cm 
in Asian men) or 




maintain a healthy 
weight 
Women should 
maintain or lose 
weight through an 
appropriate balance 
of physical activity, 
caloric intake +/- 
formal behavioural 
programs (eg aim 
BMI ??25 kg/m2 in 
U.S. women) 
NR
Physical activity At least 150 mins 
of moderate 
intensity aerobic 
activity or 75 
minutes of vigorous 
Do 150 – 300 
mins/week of 
physical activity or 
aerobic exercise 
training of at least 
moderate intensity 
At least 30 mins of 
moderate intensity 
physical activity on 
most days of the 
week, preferably 
Engage in 150 
mins/ week of 
moderate-intensity 
physical activity, or 
75 minutes/ week 
of vigorous-
At least 150 
min/week of 
moderate exercise, 
75 min/week of 
vigorous exercise. 
Performed in 
Increase overall levels 
of sustained physical 
activity and avoid 
prolonged sedentary 
behaviour. Emphasize 




or 60 -150 mins/ 
week of vigorous 
intensity exercise. 
Sedentary subjects 
should start light 
intensity exercise 
programs. Perform 
in multiple bouts of 








Performed in burst 




episodes of at least 
10 min, preferably 
spread throughout 
the week. Additional 
cardiovascular 
benefits  by 
increasing moderate-
intensity to 300 
minutes/week or 150 
mins/week of 
vigorous-intensity 
other aerobic physical 
daily activities, at 
moderate intensity for 
at least 150 min/ week 
in bouts of ≥10 min, or




performed on at least 




 NR If at high risk for 















factors. FRS may 
underestimate risk 
in adults with 
depression. 
 NR  NR NR
* Advise people who would benefit from LDL lowering; ^ Advise those who would benefit from BP lowering; €, in line with the Four commonly used methods to 
increase physical activity (NICE public health guidance 2); *, in line with the national guidance for the general population (see physical activity guidelines for adults at 
NHS choices);
Abbreviation: ABI , ankle brachial index, CBT , cognitive behavioural therapy, CEA , cost-effectiveness analysis, CAC , coronary artery calcium, CHD , coronary heart 
disease, CKD , chronic kidney disease, CVD , cardiovascular disease, DASH , Dietary Approaches to Stop Hypertension, DM , diabetes mellitus, FHx , family history, HDL-
C , high-density lipoprotein cholesterol, LDL-C , low-density lipoprotein cholesterol, LVH , left ventricular hypertrophy, NHS , National Health Service, NR , not reported, 





((MH "Cardiovascular Diseases") OR (MH "Aortic Aneurysm+") OR (MH “Myocardial Ischemia+”)  OR (MH “Arteriosclerosis+”) OR (MH 
“Cerebrovascular Disorders+”) OR (MH ”Peripheral Vascular Diseases”) OR (MH “Heart Failure, Congestive+”) OR (TX (cardiovascular N3 
disease*)) OR (TX (coronary N3 disease*)) OR (TX heart disease*) OR (TX (stroke* or cerebrovasc* or cva*)) OR (TX (aort* N5 
aneurysm)) OR (TX (abdominal N5 aneurysm)) OR (TX (thoracoabdominal N5 aneurysm)) OR (TX (arteri* N3 occlusi*)) OR (TX (arteri* N3 
stenosis)) OR (TX (peripher* N5 occlusi*)) OR (TX (peripher* N5 arteri*)) OR (TX (peripher* N5 vascular)) OR (TX heart failure) OR (TX 
atherosclerosis) OR (TX arteriosclerosis) OR (MH 
“Hypertension”) OR (MH “Hyperlipidemia”) OR (MH “Diabetes Mellitus“) OR (TX hypertension) OR (TX hyperlipid?emia) OR (TX 
dyslipid?emia) OR (TX cholesterol) OR (TX diabetes) OR (TX metabolic syndrome)) 
AND 
((MH "Cardiovascular Diseases/PC") OR (MH “Preventive Health Care”) OR (MH “Health Screening”)  OR (MH “Risk Assessment”) OR (MH 
“Cardiovascular Risk Factors”) OR (MH “Early Intervention”) OR (TX prevent*) OR (TX (risk N3 reduc*)) OR (TX (risk N3 manage*)) OR 
(TX (risk N3 managing)) OR (TX (risk N3 intervent*)) OR (TX (risk N3 assess*)) OR (TX early N3 interven*) OR (TX early N3 detect*) 
OR (TX early N3 diagnos*) OR (TX screen*) OR (TX (periodic N3 exam*)) OR (TX (periodic N3 evaluat*)) OR (TX (periodic N3 check*))) 
AND 
((PT Practice Guidelines) OR (TI guideline*) OR (TI guidance*) OR (TI (position paper or position stand)) OR (TI statement*) OR (TI 
recommendation*) OR (TI consensus) OR (TI practice parameter*) OR (TI standards)) 
NOT 
((PT commentary) OR (PT letter) OR (PT editorial)) 
Limit results to English l
9
Supplementary Table A4 -  Reporting Checklist for Systematic Review
Section/topic # Checklist item Reported on page # 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number. 
2
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known. 4
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS). 
5
METHODS 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), 
and, if available, provide registration information including registration number. 
As previously 
published (5)
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics 
(e.g., years considered, language, publication status) used as criteria for eligibility, giving 
rationale. 
5-6
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched. 
5-6
Search 8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated. 
Supplementary 
material
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis). 
6-7
10
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators. 
6-7
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and 
any assumptions and simplifications made. 
5-6
Section/topic # Checklist item Reported on page # 
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis. 
Not applicable
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). Not applicable
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis. 
7
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies). 
Not applicable
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified. 
Not applicable
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram. 
7-8
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, 
PICOS, follow-up period) and provide the citations. 
7
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment 
(see item 12). 
Not applicable
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence intervals, 




Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency. 
7-13
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). Not applicable
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]). 
Not applicable
DISCUSSION 
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy 
makers). 
14
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias). 
16
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research. 
16
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of 
data); role of funders for the systematic review. 
18
